| 1 |
Fukuchi T, Kawashima K, Koga H, Utsunomiya R, Sugiyama K, Shimazu K, Eguchi T, Ishihara S. Induction of mucosal healing by intensive granulocyte/monocyte adsorptive apheresis (GMA) without use of corticosteroids in patients with ulcerative colitis: long-term remission maintenance after induction by GMA and efficacy of GMA re-treatment upon relapse. J Clin Biochem Nutr . [DOI: 10.3164/jcbn.21-112] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 2 |
Vasile Balaban D, Jinga M. Apheresis in Inflammatory Bowel Disease: Current Evidence. Crohn’s Disease Recent Advances 2021. [DOI: 10.5772/intechopen.93605] [Reference Citation Analysis]
|
| 3 |
Ishiguro Y, Ohmori T, Umemura K, Iizuka M. Factors associated with the outcomes in ulcerative colitis patients undergoing granulocyte and monocyte adsorptive apheresis as remission induction therapy: A multicenter cohort study. Ther Apher Dial 2021;25:502-12. [PMID: 33029920 DOI: 10.1111/1744-9987.13594] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 4 |
Chen XL, Mao JW, Wang YD. Selective granulocyte and monocyte apheresis in inflammatory bowel disease: Its past, present and future. World J Gastrointest Pathophysiol 2020; 11(3): 43-56 [PMID: 32435521 DOI: 10.4291/wjgp.v11.i3.43] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 5 |
Li N, Mao J, Tang H, Zhu L, Tan X, Bi J, Wu H, Chen X, Wang Y. Efficacy and safety of adsorptive granulomonocytapheresis in Chinese patients with ulcerative colitis: A retrospective analysis of 50 cases with focus on factors impacting clinical efficacy. J Clin Apher 2020;35:271-80. [PMID: 32378240 DOI: 10.1002/jca.21787] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 6 |
Sood A, Singh A, Sudhakar R, Midha V, Mahajan R, Mehta V, Gupta YK, Kaur K. Exclusive enteral nutrition for induction of remission in anti-tumor necrosis factor refractory adult Crohn's disease: the Indian experience. Intest Res 2020;18:184-91. [PMID: 32092799 DOI: 10.5217/ir.2019.00094] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 7 |
Saniabadi AR, Tanaka T, Yamamoto T, Kruis W, Sacco R. Granulomonocytapheresis as a cell-dependent treatment option for patients with inflammatory bowel disease: Concepts and clinical features for better therapeutic outcomes. J Clin Apher. 2019;34:51-60. [PMID: 30407662 DOI: 10.1002/jca.21670] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 8 |
Shimoyama T, Yamamoto T, Umegae S, Matsumoto K. Faecal calprotectin level for assessing endoscopic activity and predicting future clinical course in patients with moderately active ulcerative colitis undergoing granulomonocytapheresis: a prospective cohort study. BMC Gastroenterol 2018;18:120. [PMID: 30068300 DOI: 10.1186/s12876-018-0853-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 9 |
Yamamoto T, Iida T, Ikeya K, Kato M, Matsuura A, Tamura S, Takano R, Tani S, Osawa S, Sugimoto K, Shimoyama T, Hanai H. A multicenter retrospective study aiming to identify patients who respond well to adsorptive granulomonocytapheresis in moderately to severely active ulcerative colitis. Clin Transl Gastroenterol. 2018;9:170. [PMID: 29977035 DOI: 10.1038/s41424-018-0037-0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 10 |
Domènech E, Panés J, Hinojosa J, Annese V, Magro F, Sturniolo GC, Bossa F, Fernández F, González-Conde B, García-Sánchez V, Dignass A, Herrera JM, Cabriada JL, Guardiola J, Vecchi M, Portela F, Ginard D; ATTICA Study Group by the Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa [listed at the end of the article]. Addition of Granulocyte/Monocyte Apheresis to Oral Prednisone for Steroid-dependent Ulcerative Colitis: A Randomized Multicentre Clinical Trial. J Crohns Colitis 2018;12:687-94. [PMID: 29490024 DOI: 10.1093/ecco-jcc/jjy023] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 11 |
Tanaka T, Yamamoto T, Sawada K, Sacco R. Treatment options for children and adolescents with inflammatory bowel disease: is granulomonocytapheresis an effective alternative to drug therapy? Expert Rev Gastroenterol Hepatol 2017;11:749-58. [PMID: 28612637 DOI: 10.1080/17474124.2017.1341309] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 12 |
Cabriada J, Rodríguez-lago I. Granulocitoaféresis en 2017. Puesta al día. Enfermedad Inflamatoria Intestinal al Día 2017;16:62-69. [DOI: 10.1016/j.eii.2016.12.001] [Reference Citation Analysis]
|
| 13 |
Rodríguez-lago I, Gómez-irwin L, Fernández E, Higuera R, Cabriada JL. Granulocyte-Monocyte Apheresis as an Adjuvant Therapy to Anti-Tumor Necrosis Factor Drugs for Ulcerative Colitis: Granulocyte-Monocyte Apheresis After Anti-TNF Failure. Ther Apher Dial 2017;21:26-30. [DOI: 10.1111/1744-9987.12485] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 14 |
Kanai T. Leukocytapheresis Therapy of Inflammatory Bowel Disease. Crohn's Disease and Ulcerative Colitis 2017. [DOI: 10.1007/978-3-319-33703-6_49] [Reference Citation Analysis]
|
| 15 |
Edfors K, Ståhlberg D, Söderman C. Retrospective Single Center Study of Granulocyte Monocyte Adsorption Apheresis Treatment in Inflammatory Bowel Disease. Ther Apher Dial 2016;20:79-85. [PMID: 26841133 DOI: 10.1111/1744-9987.12336] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 16 |
Tanida S, Ozeki K, Mizoshita T, Tsukamoto H, Katano T, Kataoka H, Kamiya T, Joh T. Managing refractory Crohn's disease: challenges and solutions. Clin Exp Gastroenterol 2015;8:131-40. [PMID: 25914555 DOI: 10.2147/CEG.S61868] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 17 |
Fowler S, Jones J, Hull PR, Ghosh S. Extracorporeal photopheresis for the treatment of Crohn's disease. Transfusion and Apheresis Science 2015;52:183-6. [DOI: 10.1016/j.transci.2015.02.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 18 |
Osada T, Watanabe S. Current Treatment Options for Inflammatory Bowel Diseases and Future Perspectives. Juntendo Medical Journal 2015;61:588-596. [DOI: 10.14789/jmj.61.588] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 19 |
De Cassan C, Savarino E, Marson P, Tison T, Hatem G, Sturniolo GC, D’Incà R. Granulo-monocyto apheresis is more effective in mild ulcerative colitis than in moderate to severe disease. World J Gastroenterol 2014; 20(45): 17155-17162 [PMID: 25493030 DOI: 10.3748/wjg.v20.i45.17155] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 20 |
Olsen HH, Muratov V, Cederlund K, Lundahl J, Eklund A, Grunewald J. Therapeutic granulocyte and monocyte apheresis (GMA) for treatment refractory sarcoidosis: a pilot study of clinical effects and possible mechanisms of action. Clin Exp Immunol 2014;177:712-9. [PMID: 24773420 DOI: 10.1111/cei.12360] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 21 |
Saniabadi AR, Tanaka T, Ohmori T, Sawada K, Yamamoto T, Hanai H. Treating inflammatory bowel disease by adsorptive leucocytapheresis: A desire to treat without drugs. World J Gastroenterol 2014; 20(29): 9699-9715 [PMID: 25110409 DOI: 10.3748/wjg.v20.i29.9699] [Cited by in CrossRef: 54] [Cited by in F6Publishing: 57] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 22 |
Ravasio R, De Silvestro G, Saggioro A, Sturniolo GC, Vernia P. Valutazione economica del sistema di aferesi per la rimozione di granulociti e macrofagi (Adacolumn®) rispetto a biologico nel trattamento della colite ulcerosa moderata-severa in pazienti steroido-dipendenti o resistenti in Italia. G Ital Health Technol Assess 2013;6:55-64. [DOI: 10.1007/s40269-013-0008-y] [Reference Citation Analysis]
|
| 23 |
Sacco R, Romano A, Mazzoni A, Bertini M, Federici G, Metrangolo S, Parisi G, Nencini C, Giampietro C, Bertoni M, Tumino E, Scatena F, Bresci G. Granulocytapheresis in steroid-dependent and steroid-resistant patients with inflammatory bowel disease: a prospective observational study. J Crohns Colitis 2013;7:e692-7. [PMID: 23870727 DOI: 10.1016/j.crohns.2013.06.012] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 3.6] [Reference Citation Analysis]
|
| 24 |
Bamba T, Yamamoto T, Umegae S, Matsumoto K. Effects of preoperative leukocytapheresis on inflammatory cytokines following surgery for ulcerative colitis: a prospective randomized study. J Clin Apher. 2014;29:107-112. [PMID: 24000140 DOI: 10.1002/jca.21299] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 25 |
Sands BE, Katz S, Wolf DC, Feagan BG, Wang T, Gustofson LM, Wong C, Vandervoort MK, Hanauer S. A randomised, double-blind, sham-controlled study of granulocyte/monocyte apheresis for moderate to severe Crohn's disease. Gut 2013;62:1288-94. [PMID: 22760005 DOI: 10.1136/gutjnl-2011-300995] [Cited by in Crossref: 39] [Cited by in F6Publishing: 41] [Article Influence: 3.9] [Reference Citation Analysis]
|
| 26 |
Tanaka T, Sugiyama S, Goishi H, Kajihara T, Akagi M, Miura T. Treatment of children and adolescents with ulcerative colitis by adsorptive depletion of myeloid lineage leucocytes as monotherapy or in combination with low dose prednisolone after failure of first-line medications. BMC Gastroenterol. 2013;13:130. [PMID: 23961883 DOI: 10.1186/1471-230x-13-130] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 27 |
Tanaka T, Sugiyama S, Goishi H, Kajihara T, Akagi M, Miura T. Treatment of children and adolescents with ulcerative colitis by adsorptive depletion of myeloid lineage leucocytes as monotherapy or in combination with low dose prednisolone after failure of first-line medications. BMC Gastroenterol. 2013;13:130. [PMID: 23961883 DOI: 10.1016/s1873-9946(13)60351-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 28 |
Tominaga K, Nakano M, Hoshino M, Kanke K, Hiraishi H. Efficacy, safety and cost analyses in ulcerative colitis patients undergoing granulocyte and monocyte adsorption or receiving prednisolone. BMC Gastroenterol. 2013;13:41. [PMID: 23452668 DOI: 10.1186/1471-230x-13-41] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 29 |
Takahashi H, Sugawara K, Sugimura M, Iwabuchi M, Mano Y, Ukai K, Tadokoro K. Flare up of ulcerative colitis during pregnancy treated by adsorptive granulocyte and monocyte apheresis: therapeutic outcomes in three pregnant patients. Arch Gynecol Obstet. 2013;288:341-347. [PMID: 23404436 DOI: 10.1007/s00404-013-2748-5] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 30 |
Yokoyama Y, Kawai M, Fukunaga K, Kamikozuru K, Nagase K, Nogami K, Kono T, Ohda Y, Iimuro M, Hida N, Nakamura S, Miwa H, Matsumoto T. Looking for predictive factors of clinical response to adsorptive granulocyte and monocyte apheresis in patients with ulcerative colitis: markers of response to GMA. BMC Gastroenterol. 2013;13:27. [PMID: 23399416 DOI: 10.1186/1471-230x-13-27] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 31 |
Ikeda S, Takahashi H, Suga Y, Eto H, Etoh T, Okuma K, Takahashi K, Kanbara T, Seishima M, Morita A, Imai Y, Kanekura T. Therapeutic depletion of myeloid lineage leukocytes in patients with generalized pustular psoriasis indicates a major role for neutrophils in the immunopathogenesis of psoriasis. J Am Acad Dermatol 2013;68:609-17. [PMID: 23332516 DOI: 10.1016/j.jaad.2012.09.037] [Cited by in Crossref: 83] [Cited by in F6Publishing: 84] [Article Influence: 8.3] [Reference Citation Analysis]
|
| 32 |
Vecchi M, Vernia P, Riegler G, D’Incà R, Annese V, Bagnoli S. Therapeutic landscape for ulcerative colitis: where is the Adacolumn(®) system and where should it be? Clin Exp Gastroenterol. 2013;6:1-7. [PMID: 23323022 DOI: 10.2147/ceg.s33275] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 33 |
Shiraki M, Yamamoto T. Steroid-sparing strategies in the management of ulcerative colitis: Efficacy of leukocytapheresis. World J Gastroenterol 2012; 18(41): 5833-5838 [PMID: 23139598 DOI: 10.3748/wjg.v18.i41.5833] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 34 |
Fukunaga K, Yokoyama Y, Kamokozuru K, Nagase K, Nakamura S, Miwa H, Matsumoto T. Adsorptive granulocyte/monocyte apheresis for the maintenance of remission in patients with ulcerative colitis: a prospective randomized, double blind, sham-controlled clinical trial. Gut Liver. 2012;6:427-433. [PMID: 23170145 DOI: 10.5009/gnl.2012.6.4.427] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 35 |
Yamamoto T, Umegae S, Matsumoto K. Long-term clinical impact of early introduction of granulocyte and monocyte adsorptive apheresis in new onset, moderately active, extensive ulcerative colitis. J Crohns Colitis 2012;6:750-5. [PMID: 22398094 DOI: 10.1016/j.crohns.2011.12.009] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 36 |
Kato S, Hosomi E, Amano F, Kobayashi T, Kani K, Yamamoto R, Ogawa T, Matsuda A, Sato Y, Izaki S, Mitarai T, Yakabi K. The efficacy of intensive granulocyte and monocyte adsorption apheresis in a patient with Crohn's disease complicated by extensive subcutaneous aseptic neutrophilic abscesses. J Crohns Colitis 2012;6:787-91. [PMID: 22386738 DOI: 10.1016/j.crohns.2012.02.005] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 37 |
Fukunaga K, Matsumoto T. Current status and future perspectives of leukocytapheresis for inflammatory bowel disease. J Gastroenterol Hepatol 2012;27:997-1003. [PMID: 22414250 DOI: 10.1111/j.1440-1746.2012.07119.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 38 |
Cabriada JL, Domènech E, Ibargoyen N, Hernández V, Clofent J, Ginard D, Gutiérrez-Ibarluzea I, Hinojosa J. Leukocytapheresis for steroid-dependent ulcerative colitis in clinical practice: results of a nationwide Spanish registry. J Gastroenterol 2012;47:359-65. [PMID: 22105230 DOI: 10.1007/s00535-011-0499-2] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 39 |
Cabriada JL. Aféresis en enfermedad inflamatoria intestinal. ¿Una opción válida? Gastroenterología y Hepatología 2012;35:22-31. [DOI: 10.1016/j.gastrohep.2011.10.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 40 |
Itagaki M, Saruta M, Iinuma T, Arihiro S, Kato T, Tajiri H. Infliximab- and immunosuppressant-resistant Crohn's disease successfully treated with adsorptive granulocyte apheresis combined with prednisolone. Case Rep Gastroenterol 2012;6:118-23. [PMID: 22761605 DOI: 10.1159/000334428] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 41 |
Kochi S, Nakamura S, Matsumoto T. Efficacy of low-dose thiopurine therapy for the induction of remission in steroid-dependent ulcerative colitis: Comparison with cytapheresis. OJGas 2012;02:9-14. [DOI: 10.4236/ojgas.2012.21002] [Reference Citation Analysis]
|
| 42 |
Yoshimura N, Tadami T, Kawaguchi T, Sako M, Yoshimoto H, Yamaka T, Takazoe M. Processed blood volume impacts clinical efficacy in patients with ulcerative colitis undergoing adsorptive depletion of myeloid lineage leucocytes. J Gastroenterol 2012;47:49-55. [PMID: 21915624 DOI: 10.1007/s00535-011-0464-0] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 43 |
Passalacqua S, Ferraro PM, Bresci G, D'Ovidio V, Astegiano M, Principi M, Testa R, D'Incà R, Valpiani D, Armuzzi A, Sablich R, Cavallaro F, Costa F, Di Leo V, Colombo E, Santini A, Aratari A, Lecis P, Saladino V, Riegler G, Marco M, Calella F, Ricci C, Guidi ML, Repaci G, Silla M. The Italian Registry of Therapeutic Apheresis: granulocyte-monocyte apheresis in the treatment of inflammatory bowel disease. A multicentric study. J Clin Apher 2011;26:332-7. [PMID: 22072543 DOI: 10.1002/jca.20315] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 44 |
Nakase H, Uza N, Matsuura M, Chiba T. Importance of CXCL16 as a biomarker for granulocytapheresis in patients with Crohn's disease. Inflamm Bowel Dis 2011;17:2211-2. [PMID: 21391290 DOI: 10.1002/ibd.21657] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 45 |
Zhu M, Xu X, Nie F, Tong J, Xiao S, Ran Z. The efficacy and safety of selective leukocytapheresis in the treatment of ulcerative colitis: a meta-analysis. Int J Colorectal Dis 2011;26:999-1007. [PMID: 21476027 DOI: 10.1007/s00384-011-1193-9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 46 |
Terao S, Yamashiro K, Tamura I, Hirano T, Ohkusa T, Kato K. Antibiotic combination therapy for steroid withdrawal in steroid-dependent ulcerative colitis. Digestion 2011;83:198-203. [PMID: 21266816 DOI: 10.1159/000321811] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 47 |
Vernia P, D’Ovidio V, Meo D. Leukocytapheresis in the treatment of inflammatory bowel disease: Current position and perspectives. Transfus Apher Sci. 2010;43:227-229. [PMID: 20817610 DOI: 10.1016/j.transci.2010.07.023] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 48 |
Ng SC, Chan FK, Sung JJ. Review article: the role of non-biological drugs in refractory inflammatory bowel disease. Aliment Pharmacol Ther 2011;33:417-27. [PMID: 21138457 DOI: 10.1111/j.1365-2036.2010.04541.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 2.1] [Reference Citation Analysis]
|
| 49 |
Hanai H, Takeda Y, Eberhardson M, Gruber R, Saniabadi AR, Winqvist O, Lofberg R. The mode of actions of the Adacolumn therapeutic leucocytapheresis in patients with inflammatory bowel disease: a concise review. Clin Exp Immunol. 2011;163:50-58. [PMID: 21078086 DOI: 10.1111/j.1365-2249.2010.04279.x] [Cited by in Crossref: 65] [Cited by in F6Publishing: 72] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 50 |
Hanai H, Takeda Y, Eberhardson M, Gruber R, Saniabadi AR, Winqvist O, Lofberg R. The mode of actions of the Adacolumn therapeutic leucocytapheresis in patients with inflammatory bowel disease: a concise review. Clin Exp Immunol 2011;163:50-8. [PMID: 21078086 DOI: 10.1111/j.1365-2249.2010.04279.x] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 51 |
Yamamoto T, Umegae S, Matsumoto K. Mucosal healing in patients with ulcerative colitis during a course of selective leukocytapheresis therapy: a prospective cohort study. Inflamm Bowel Dis 2010;16:1905-11. [PMID: 20310015 DOI: 10.1002/ibd.21260] [Cited by in Crossref: 50] [Cited by in F6Publishing: 49] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 52 |
Saniabadi AR, Hanai H. Therapeutic apheresis from the early civilizations to the twenty-first century. Gastroenterol Clin Biol 2010;34:645-8. [PMID: 20971590 DOI: 10.1016/j.gcb.2010.09.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 53 |
Tanaka T, Okanobu H, Kuga Y, Yoshifuku Y, Fujino H, Miwata T, Moriya T, Nishida T, Oya T. Clinical and endoscopic features of responders and non-responders to adsorptive leucocytapheresis: a report based on 120 patients with active ulcerative colitis. Gastroenterol Clin Biol. 2010;34:687-695. [PMID: 20934287 DOI: 10.1016/j.gcb.2010.08.007] [Cited by in Crossref: 21] [Cited by in F6Publishing: 25] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 54 |
Lindberg A, Eberhardson M, Karlsson M, Karlén P. Long-term follow-up with Granulocyte and Monocyte Apheresis re-treatment in patients with chronically active inflammatory bowel disease. BMC Gastroenterol. 2010;10:73. [PMID: 20604939 DOI: 10.1186/1471-230x-10-73] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 55 |
Takeda S, Sato T, Katsuno T, Nakagawa T, Noguchi Y, Yokosuka O, Saito Y. Adsorptive depletion of alpha4 integrin(hi)- and CX3CR1hi-expressing proinflammatory monocytes in patients with ulcerative colitis. Dig Dis Sci 2010;55:1886-95. [PMID: 19908144 DOI: 10.1007/s10620-009-0974-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 56 |
Ibargoyen-Roteta N, Gutiérrez-Ibarluzea I, Rico-Iturrioz R, López-Argumedo M, Reviriego-Rodrigo E, Cabriada-Nuño JL, Schünemann HJ. The GRADE approach for assessing new technologies as applied to apheresis devices in ulcerative colitis. Implement Sci 2010;5:48. [PMID: 20553616 DOI: 10.1186/1748-5908-5-48] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 57 |
Cabriada JL, Ibargoyen N, Hernández A, Bernal A, Castiella A. Sustained remission after steroids and leukocytapheresis induced response in steroid-dependent ulcerative colitis: results at 1 year. Dig Liver Dis 2010;42:432-5. [PMID: 19833566 DOI: 10.1016/j.dld.2009.09.001] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 58 |
Helmy A, Abdulla M, Kagevi I, Al Kahtani K. Leukocyte apheresis in the management of ulcerative colitis. Saudi J Gastroenterol 2009;15:283-7. [PMID: 19794281 DOI: 10.4103/1319-3767.56093] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 59 |
Nos P, Domènech E. Tratamiento con aféresis en la enfermedad inflamatoria intestinal. Gastroenterología y Hepatología 2009;32:509-18. [DOI: 10.1016/j.gastrohep.2009.01.183] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 60 |
Hibi T, Sameshima Y, Sekiguchi Y, Hisatome Y, Maruyama F, Moriwaki K, Shima C, Saniabadi AR, Matsumoto T. Treating ulcerative colitis by Adacolumn therapeutic leucocytapheresis: clinical efficacy and safety based on surveillance of 656 patients in 53 centres in Japan. Dig Liver Dis 2009;41:570-7. [PMID: 19211314 DOI: 10.1016/j.dld.2008.11.020] [Cited by in Crossref: 50] [Cited by in F6Publishing: 51] [Article Influence: 3.6] [Reference Citation Analysis]
|
| 61 |
Ng SC, Kamm MA. Therapeutic strategies for the management of ulcerative colitis. Inflamm Bowel Dis 2009;15:935-50. [PMID: 18985710 DOI: 10.1002/ibd.20797] [Cited by in Crossref: 56] [Cited by in F6Publishing: 54] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 62 |
Matsuda R, Koide T, Tokoro C, Yamamoto T, Godai T, Morohashi T, Fujita Y, Takahashi D, Kawana I, Suzuki S, Umemura S. Quantitive cytokine mRNA expression profiles in the colonic mucosa of patients with steroid naïve ulcerative colitis during active and quiescent disease. Inflamm Bowel Dis 2009;15:328-34. [PMID: 18942752 DOI: 10.1002/ibd.20759] [Cited by in Crossref: 62] [Cited by in F6Publishing: 56] [Article Influence: 4.4] [Reference Citation Analysis]
|
| 63 |
Bresci G. Granulocytapheresis in the treatment of patients with active ulcerative colitis. Expert Rev Gastroenterol Hepatol 2008;2:639-43. [PMID: 19072341 DOI: 10.1586/17474124.2.5.639] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 64 |
Takeda H, Suzuki Y, Takeda Y, Nishise S, Fukui T, Fujishima S, Orii T, Otake S, Sato T, Suzuki K, Nakamuara Y, Kawata S. A multi center study of granulocyte and monocyte adsorption apheresis therapy for ulcerative colitis-clinical efficacy and production of interleukin-1 receptor antagonist. J Clin Apher 2008;23:105-10. [PMID: 18449931 DOI: 10.1002/jca.20164] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 65 |
Umehara Y, Kudo M, Kawasaki M. Endoscopic findings can predict the efficacy of leukocytapheresis for steroid-naive patients with moderately active ulcerative colitis. World J Gastroenterol 2008; 14(34): 5316-5321 [PMID: 18785285 DOI: 10.3748/wjg.14.5316] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 66 |
Tanaka T, Okanobu H, Yoshimi S, Murakami E, Kogame A, Imagawa H, Numata Y, Kuga Y, Moriya T, Ohya T, Kajiyama G. In patients with ulcerative colitis, adsorptive depletion of granulocytes and monocytes impacts mucosal level of neutrophils and clinically is most effective in steroid naïve patients. Dig Liver Dis 2008;40:731-6. [PMID: 18387860 DOI: 10.1016/j.dld.2008.02.012] [Cited by in Crossref: 49] [Cited by in F6Publishing: 52] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 67 |
Sigurbjörnsson FT, Bjarnason I. Leukocytapheresis for the treatment of IBD. Nat Clin Pract Gastroenterol Hepatol. 2008;5:509-516. [PMID: 18665138 DOI: 10.1038/ncpgasthep1209] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 68 |
Danese S, Angelucci E, Stefanelli T, Omodei P, Luigiano C, Finazzi S, Pagano N, Repici A, Vecchi M, Malesci A. Cytapheresis in inflammatory bowel diseases: current evidence and perspectives. Digestion 2008;77:96-107. [PMID: 18382085 DOI: 10.1159/000122473] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 69 |
Hanai H, Iida T, Takeuchi K, Watanabe F, Maruyama Y, Kageoka M, Ikeya K, Yamada M, Kikuyama M, Iwaoka Y, Hirayama K, Nagata S, Sato Y, Hosoda Y. Intensive granulocyte and monocyte adsorption versus intravenous prednisolone in patients with severe ulcerative colitis: an unblinded randomised multi-centre controlled study. Dig Liver Dis 2008;40:433-40. [PMID: 18296130 DOI: 10.1016/j.dld.2008.01.007] [Cited by in Crossref: 32] [Cited by in F6Publishing: 35] [Article Influence: 2.1] [Reference Citation Analysis]
|
| 70 |
Sakuraba A, Sato T, Naganuma M, Morohoshi Y, Matsuoka K, Inoue N, Takaishi H, Ogata H, Iwao Y, Hibi T. A pilot open-labeled prospective randomized study between weekly and intensive treatment of granulocyte and monocyte adsorption apheresis for active ulcerative colitis. J Gastroenterol 2008;43:51-6. [PMID: 18297436 DOI: 10.1007/s00535-007-2129-6] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 71 |
Martín de Carpi J, Vilar P, Prieto G, García Novo MD, Ribes C, Varea V. Safety and efficacy of granulocyte and monocyte adsorption apheresis in paediatric inflammatory bowel disease: a prospective pilot study. J Pediatr Gastroenterol Nutr 2008;46:386-91. [PMID: 18367949 DOI: 10.1097/MPG.0b013e31815604e5] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 72 |
Matsumoto T, Fukunaga K, Kamikozuru K, Tozawa K, Yokoyama Y, Kusaka T, Onishi K, Miwa H, Nakamura S. Cytapheresis as a Non-Pharmacological Therapy for Inflammatory Bowel Disease. Transfus Med Hemother. 2008;35:18-23. [PMID: 21547106 DOI: 10.1159/000111763] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 73 |
Noguchi A, Watanabe K, Narumi S, Yamagami H, Fujiwara Y, Higuchi K, Oshitani N, Arakawa T. The production of interferon-gamma-inducible protein 10 by granulocytes and monocytes is associated with ulcerative colitis disease activity. J Gastroenterol 2007;42:947-56. [PMID: 18085351 DOI: 10.1007/s00535-007-2118-9] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 74 |
Abreu MT, Plevy S, Sands BE, Weinstein R. Selective leukocyte apheresis for the treatment of inflammatory bowel disease. J Clin Gastroenterol 2007;41:874-88. [PMID: 18090155 DOI: 10.1097/MCG.0b013e3180479435] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 75 |
Saniabadi AR, Hanai H, Fukunaga K, Sawada K, Shima C, Bjarnason I, Lofberg R. Therapeutic leukocytapheresis for inflammatory bowel disease. Transfus Apher Sci. 2007;37:191-200. [PMID: 17974479 DOI: 10.1016/j.transci.2007.08.003] [Cited by in Crossref: 66] [Cited by in F6Publishing: 68] [Article Influence: 4.1] [Reference Citation Analysis]
|
| 76 |
Yokoyama Y, Fukunaga K, Fukuda Y, Tozawa K, Kamikozuru K, Ohnishi K, Kusaka T, Kosaka T, Hida N, Ohda Y, Miwa H, Matsumoto T. Demonstration of low-regulatory CD25High+CD4+ and high-pro-inflammatory CD28-CD4+ T-Cell subsets in patients with ulcerative colitis: modified by selective granulocyte and monocyte adsorption apheresis. Dig Dis Sci 2007;52:2725-31. [PMID: 17404876 DOI: 10.1007/s10620-006-9560-z] [Cited by in Crossref: 53] [Cited by in F6Publishing: 50] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 77 |
Bianchi Porro G, Cassinotti A, Ferrara E, Maconi G, Ardizzone S. Review article: the management of steroid dependency in ulcerative colitis. Aliment Pharmacol Ther 2007;26:779-94. [PMID: 17767462 DOI: 10.1111/j.1365-2036.2007.03334.x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 35] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 78 |
Yamamoto T, Saniabadi AR, Maruyama Y, Umegae S, Matsumoto K. Factors affecting clinical and endoscopic efficacies of selective leucocytapheresis for ulcerative colitis. Dig Liver Dis 2007;39:626-33. [PMID: 17532273 DOI: 10.1016/j.dld.2007.04.007] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 79 |
Panés J, Guilera M, Ginard D, Hinojosa J, González-Carro P, González-Lara V, Varea V, Domènech E, Badia X. Treatment cost of ulcerative colitis is apheresis with Adacolumn cost-effective? Dig Liver Dis 2007;39:617-25. [PMID: 17531555 DOI: 10.1016/j.dld.2007.03.007] [Cited by in Crossref: 31] [Cited by in F6Publishing: 35] [Article Influence: 1.9] [Reference Citation Analysis]
|
| 80 |
Aoki H, Nakamura K, Yoshimatsu Y, Tsuda Y, Irie M, Fukuda K, Hosoe N, Takada N, Shirai K, Suzuki Y. Adacolumn selective leukocyte adsorption apheresis in patients with active ulcerative colitis: clinical efficacy, effects on plasma IL-8, and expression of Toll-like receptor 2 on granulocytes. Dig Dis Sci 2007;52:1427-33. [PMID: 17394078 DOI: 10.1007/s10620-006-9406-8] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 81 |
Caprilli R, D'Ovidio V. Leukocytapheresis as promising therapy for inflammatory bowel disease. Dig Liver Dis 2007;39:435-7. [PMID: 17379590 DOI: 10.1016/j.dld.2007.02.003] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 82 |
Ricart E, Esteve M, Andreu M, Casellas F, Monfort D, Sans M, Oudovenko N, Lafuente R, Panés J. Evaluation of 5 versus 10 granulocyteaphaeresis sessions in steroid-dependent ulcerative colitis: A pilot, prospective, multicenter, randomized study. World J Gastroenterol 2007; 13(15): 2193-2197 [PMID: 17465500 DOI: 10.3748/wjg.v13.i15.2193] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 83 |
Luis Cabriada-nuño J, Bernal-martínez A, Hernández-martín A, Antonio Arévalo-serna J, Fernández-prado E. Aféresis leucocitaria en la inducción de la remisión y retirada de corticoides en la colitis ulcerosa corticodependiente. Diálisis y Trasplante 2007;28:47-55. [DOI: 10.1016/s1886-2845(07)71352-8] [Reference Citation Analysis]
|
| 84 |
González Carro P, Pérez Roldán F, Roncero García Escribano O, Lafuente R, Legaz Huidobro ML, Amigo Echenagusía A. Case report: combination therapy with granulocyte apheresis and infliximab for refractory Crohn's disease. J Clin Apher 2006;21:249-51. [PMID: 16607627 DOI: 10.1002/jca.20093] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 85 |
Hanai H. Positions of selective leukocytapheresis in the medical therapy of ulcerative colitis. World J Gastroenterol 2006; 12(47): 7568-7577 [PMID: 17171783 DOI: 10.3748/wjg.v12.i47.7568] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 38] [Article Influence: 1.9] [Reference Citation Analysis]
|
| 86 |
Suzuki Y, Yoshimura N, Fukuda K, Shirai K, Saito Y, Saniabadi AR. A retrospective search for predictors of clinical response to selective granulocyte and monocyte apheresis in patients with ulcerative colitis. Dig Dis Sci 2006;51:2031-8. [PMID: 17004123 DOI: 10.1007/s10620-006-9199-9] [Cited by in Crossref: 47] [Cited by in F6Publishing: 40] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 87 |
Nos Mateu P. Nuevos tratamientos y aproximaciones diagnósticas en la colitis ulcerosa. Gastroenterología y Hepatología 2006;29:52-6. [DOI: 10.1157/13098295] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 88 |
Modesto I, Scimeca D, Orlando A, Cottone M. Leukocytapheresis in patients with moderate-severe steroid-dependant ulcerative colitis: clinical response without endoscopic response. Inflamm Bowel Dis 2006;12:1009-10. [PMID: 17012976 DOI: 10.1097/01.mib.0000235098.24478.e0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 89 |
Yamamoto T, Saniabadi AR, Umegae S, Matsumoto K. Impact of selective leukocytapheresis on mucosal inflammation and ulcerative colitis: cytokine profiles and endoscopic findings. Inflamm Bowel Dis 2006;12:719-26. [PMID: 16917227 DOI: 10.1097/00054725-200608000-00008] [Cited by in Crossref: 38] [Cited by in F6Publishing: 31] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 90 |
Watanabe K, Oshitani N, Kamata N, Inagawa M, Yamagami H, Higuchi K, Arakawa T. Efficacy and endoscopic prediction of cytapheresis therapy in patients with refractory and steroid-dependent ulcerative colitis. Aliment Pharmacol Ther Symp Series 2006;2:147-52. [DOI: 10.1111/j.1746-6342.2006.00038.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 91 |
Domènech E. Inflammatory bowel disease: current therapeutic options. Digestion 2006;73 Suppl 1:67-76. [PMID: 16498254 DOI: 10.1159/000089781] [Cited by in Crossref: 53] [Cited by in F6Publishing: 54] [Article Influence: 3.1] [Reference Citation Analysis]
|
| 92 |
Manoj K, Sigurbjornsson FT, Bjarnason I. Leucocyte apheresis for ulcerative colitis: Where do we stand? Dig Liver Dis 2006;38:394-6. [PMID: 16551515 DOI: 10.1016/j.dld.2006.02.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 93 |
Kanai T, Hibi T, Watanabe M. The logics of leukocytapheresis as a natural biological therapy for inflammatory bowel disease. Expert Opinion on Biological Therapy 2006;6:453-66. [DOI: 10.1517/14712598.6.5.453] [Cited by in Crossref: 35] [Cited by in F6Publishing: 37] [Article Influence: 2.1] [Reference Citation Analysis]
|
| 94 |
González-lara V, Marín-jiménez I. Nuevas perspectivas en aféresis terapéutica en la enfermedad inflamatoria intestinal crónica. Diálisis y Trasplante 2006;27:46-58. [DOI: 10.1016/s1886-2845(06)71012-8] [Reference Citation Analysis]
|
| 95 |
Cabriada JL, Doménech E, Gomollón F, González-Carro P, González-Lara V, Hinojosa J, Jiménez-López CE, Nos P, Obrador A, Panès J, Saro C, Varea V, Lafuente R, Guilera M. [Consensus document on the use of granulocytapheresis in patients with inflammatory bowel disease]. Gastroenterol Hepatol 2006;29:85-92. [PMID: 16448611 DOI: 10.1157/13083905] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 96 |
Yamamoto T, Umegae S, Matsumoto K. Safety and clinical efficacy of granulocyte and monocyte adsorptive apheresis therapy for ulcerative colitis. World J Gastroenterol 2006; 12(4): 520-525 [PMID: 16489663 DOI: 10.3748/wjg.v12.i4.520] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 32] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 97 |
Therapy of inflammatory immune diseases. 1) Leukocytapheresis therapy for inflammatory immune diseases. J Jpn Soc Intern Med 2006;95:1775-1780. [DOI: 10.2169/naika.95.1775] [Reference Citation Analysis]
|
| 98 |
Yanaru-Fujisawa R, Matsumoto T, Nakamura S, Kochi S, Iida M, Kohda F, Hirahashi M, Yao T, Mibu R. Granulocyte apheresis for pouchitis with arthritis and pyoderma gangrenosum after restorative proctocolectomy for ulcerative colitis: a case report. Inflamm Bowel Dis 2005;11:780-1. [PMID: 16043996 DOI: 10.1097/01.mib.0000172558.39767.b7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 99 |
Katz S. Update in medical therapy of ulcerative colitis: newer concepts and therapies. J Clin Gastroenterol 2005;39:557-69. [PMID: 16000921 DOI: 10.1097/01.mcg.0000170735.43887.3a] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 100 |
Sanmartí R, Marsal S, Valverde J, Casado E, Lafuente R, Kashiwagi N, Rodriguez-cros J, Erra A, Reina D, Gratacós J. Adsorptive granulocyte/monocyte apheresis for the treatment of refractory rheumatoid arthritis: an open pilot multicentre trial. Rheumatology 2005;44:1140-4. [DOI: 10.1093/rheumatology/keh701] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 0.9] [Reference Citation Analysis]
|
